source
- Biokin's EGFR-HER3 bispecific ADC succeeds in late-stage Chinese lung cancer trialChinese biotech Biokin announced that its EGFRxHER3 bispecific antibody-drug conjugate met its primary endpoint in a late-stage trial in a genetically defined subset of non-small cell lung cancer (…
- AI fuels a parallel, unregulated medical ecosystem outside traditional careArya Rao, a Harvard‑MIT M.D.-Ph.D. candidate, and Marc Succi, a Harvard radiology professor, argue that financial incentives are pulling major AI firms into health care, creating a shadow system se…